Donald Trump’s newest tariff threats have added volatility to world stock markets, with India rising as a key participant in the US president’s commerce realignment technique.
India put a 9.5% tariff on US items, whereas the US imposes simply 3% on Indian merchandise. As reciprocal tariffs loom, industries like vehicles, prescribed drugs, textiles, and metal are in danger. Despite a brief rally this week, the Nifty stays down 14% from its peak, with smallcaps in bear market territory. Over $15 billion has been pulled out by Foreign Institutional Investors (FIIs) in 2025 alone.
Foreign Portfolio Investors (FPIs) have maintained their promoting pattern in Indian equities this March, with whole fairness outflows reaching Rs 24,753 crore as of March 7, bringing the year-to-date whole to Rs 1,37,354 crore in CY25, based on ET report.
Volatility and threat aversion
India is especially susceptible to tariff hikes, with key sectors dealing with important threats. The Indian Rupee has weakened, and overseas funding is retreating because of considerations a couple of slowdown.
Ross Maxwell, Global Strategy Operations Lead at VT Markets mentioned that India’s vehicle, pharmaceutical, textiles, and metal sectors could face extreme impacts. However, India’s diplomatic method—centered on commerce negotiations and tariff rationalization—could assist mitigate dangers. YES Securities suggests decreasing tariffs on US imports like metal and inspiring American corporations like Tesla to enter India, which could function leverage towards potential retaliatory tariffs.
Temporary negotiations
VK Vijayakumar, Chief Investment Strategist at Geojit Financial Services, explains that markets understand Trump’s strikes as momentary negotiations relatively than long-term tariff impositions, acknowledging that sustained tariffs could harm the US financial system. In response, China and Germany have already carried out home stimulus measures to counterbalance the results of Trump’s insurance policies, including one other layer of complexity to the world financial panorama
Pharma sector and market sentiment
The pharmaceutical sector, which holds 35% of the US market, faces short-term challenges however could profit in the long run because of India’s aggressive benefit over China. Amisha Vora, Chairperson & MD of PL Group, emphasised that regardless of tariff considerations, India stays extra aggressive than China, which faces a 20% tariff. Sandip Sabharwal, a market professional, identified that large-cap pharma shares like Sun Pharma and Lupin have already skilled sell-offs however stay well-positioned until tariffs escalate considerably.
Despite world uncertainties, Indian markets present resilience. Vinod Nair, Head of Research at Geojit Financial Services, famous that India’s markets have remained robust regardless of fairness outflows from rising markets.
Amisha Vora sees the present dip as an funding alternative. “With ongoing reforms and India’s demographic advantage, the market will likely perform better, even amidst trade wars,” Vora informed ET suggesting a possible correction of 4-5% in the brief time period.
(Disclaimer: The opinions, analyses and proposals expressed herein are these of brokerage and don’t mirror the views of The Times of India. Always seek the advice of with a certified funding advisor or monetary planner earlier than making any funding choices.)